Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stage I Prostate Adenocarcinoma AJCC v7 1Prostatic Neoplasms 1Prostate Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 54enzalutamide 47apalutamide 37Specimen Handling 37Androgen Antagonists 34Abiraterone Acetate 32Prednisone 29darolutamide 28Radiosurgery 27Pluvicto 23Docetaxel 23abiraterone 22Radiotherapy 21Leuprolide 19Biopsy 17relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14Surveys and Questionnaires 13gallium 68 PSMA-11 12Triptorelin Pamoate 12Gonadotropin-Releasing Hormone 12Radiation 11Nivolumab 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11cabazitaxel 10bicalutamide 10X-Rays 10Standard of Care 10Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Salicylic Acid × 90 days × Clear all
NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡